Skip Navigation LinksHome > June 2013 - Volume 21 - Issue 3 > Sublingual immunotherapy and quality of life
Current Opinion in Otolaryngology & Head & Neck Surgery:
doi: 10.1097/MOO.0b013e32835fcb22
ALLERGY: Edited by Sandra Lin

Sublingual immunotherapy and quality of life

Laury, Adrienne M.a; Schlosser, Rodney J.b; Wise, Sarah K.a

Collapse Box

Abstract

Purpose of review

Sublingual immunotherapy (SLIT) has been shown to be a new and promising treatment for people with various allergic syndromes. Several studies have examined its efficacy. However, significantly fewer investigations have explored its specific impact on the patient's quality of life (QOL).

Recent findings

SLIT has an excellent safety profile, superior in many ways to subcutaneous immunotherapy (SCIT). Additionally, SLIT significantly decreases the use of allergy medications, as well as decreasing the money spent on allergy symptom control. Finally, SLIT has been shown to improve the patient's QOL when compared to placebo or even second-generation antihistamines.

Summary

Increasing data support the use of SLIT as a well tolerated, cost-effective, and time-efficient modality for the treatment of multiple allergic syndromes. However, additional studies are needed, particularly QOL studies which compare SLIT to the FDA-approved SCIT.

© 2013 Wolters Kluwer Health | Lippincott Williams & Wilkins

Login

Search for Similar Articles
You may search for similar articles that contain these same keywords or you may modify the keyword list to augment your search.